Tempest Begin Period Cash Flow from 2010 to 2024
| TPST Stock | USD 0.87 0.01 1.12% |
Begin Period Cash Flow | First Reported 2012-03-31 | Previous Quarter 32.3 M | Current Value 31.1 M | Quarterly Volatility 23.6 M |
Check Tempest Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tempest Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 361.9 K, Interest Expense of 1.5 M or Selling General Administrative of 15.4 M, as well as many indicators such as Price To Sales Ratio of 1.36, Dividend Yield of 0.0 or PTB Ratio of 3.14. Tempest financial statements analysis is a perfect complement when working with Tempest Therapeutics Valuation or Volatility modules.
Tempest | Begin Period Cash Flow |
Latest Tempest Therapeutics' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Tempest Therapeutics over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Tempest Therapeutics' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tempest Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Tempest Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 24,433,493 | |
| Geometric Mean | 16,026,002 | |
| Coefficient Of Variation | 85.64 | |
| Mean Deviation | 16,976,459 | |
| Median | 18,078,000 | |
| Standard Deviation | 20,924,209 | |
| Sample Variance | 437.8T | |
| Range | 70.1M | |
| R-Value | 0.50 | |
| Mean Square Error | 352.9T | |
| R-Squared | 0.25 | |
| Significance | 0.06 | |
| Slope | 2,346,389 | |
| Total Sum of Squares | 6129.5T |
Tempest Begin Period Cash Flow History
About Tempest Therapeutics Financial Statements
Tempest Therapeutics shareholders use historical fundamental indicators, such as Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Tempest Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Tempest Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Tempest Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 31.6 M | 30 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.